Chemoradiotherapy after curative surgery for locally advanced pancreatic cancer: A 20-year single center experience. (March 2021)

• Record Type: Journal Article
• Authors: Weibel, P.; Pavic, M.; Lombriser, N.; Gutknecht, S.; Weber, M.
• Is Part Of: Surgical oncology. Volume 36(2021)
• Page Start: 36
• Page End: 41
• Publication Date: 2021-03
• Subjects: Pancreatic adenocarcinoma -- Pancreatic cancer -- Adjuvant therapy -- Chemoradiotherapy -- Radiation therapy; Cancer -- Surgery -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Electronic journals; 616.994059
• DOI: 10.1016/j.suronc.2020.11.012
• Languages: English
• ISSNs: 0960-7404

Abstract

Abstract: Introduction: Pancreatic adenocarcinoma (PAC) is a highly malignant tumor with relevant morbidity and mortality. The role of adjuvant chemoradiotherapy (CRT) for primarily resected tumors remains controversial. We aimed to assess the outcome of patients treated at our institution with postoperative CRT for PAC. Methods: We present a retrospective case series of patients with pancreatic adenocarcinoma at a single center in Switzerland. These patients were treated by primary surgery followed by adjuvant CRT between 1995 and 2015. The results were compared with published data. Results: Median follow-up for the 60 patients was 33 months (range 19.9–193.9); median overall survival (OS) for patients undergoing a resection followed by combined CRT was 25.5 months. Overall, disease-free survival (DFS) was 15.2 months. A local recurrence occurred in 14 patients (23.3%) after a median time of 8.8 months, and in 43 patients (71.7%) distant metastasis was demonstrated with a median time to metastasis of 10.6 months. Conclusion: This retrospective study represents one of the sole reviews of outcome data after adjuvant CRT in resected PAC in Europe within the past years. OS was comparable to that of other institutional outcome data published previously but inferior when compared to most recent published results with an intense chemotherapy. However, not all patients are suitable to undergo such an intense chemotherapy with modified FOLFIRINOX after the extensive surgery for the PAC – these patients could benefit from adding adjuvant CRT to a less intensive chemotherapy with gemcitabine to enhance the benefit regarding locoregional recurrence-free survival. Highlights: We investigated overall survival after resection of pancreatic cancer with adjuvant chemoradiotherapy. Our cohort treated with chemoradiotherapy showed comparable overall survival to previously published data which have more favorable pathologic disease. We recommend chemoradiotherapy as adjuvant treatment in patients with pancreatic cancer when modified FOLFIRINOX is too demanding.